Related Experiment Video
Updated: Jun 25, 2026

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
Published on: December 15, 2023
Automated Pharmacometric Model Development by Leveraging Low-Dimensional Neural ODEs and LASSO Regression
Dominic Stefan Bräm1, Bernhard Steiert2, Britta Steffens1
1Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel UKBB, Basel, Switzerland.
Abstract:
Current pharmacometrics (PMX) model development is a manual process with iterative model building, fitting, and evaluation, which can be resource-intensive and time-consuming. Existing automated model development approaches utilize algorithms that still rely on iterative processes and perform model selection based on goodness-of-fit criteria. Recent advances in machine learning and artificial intelligence, particularly neural ordinary differential equations (NODEs), have demonstrated strong potential for characterizing complex pharmacokinetic (PK) and pharmacodynamic (PD) dynamics directly from data. However, NODEs are inherently black-box models, which limits their interpretability and their ability to provide mechanistic insights, both of which are essential in PMX. We recently presented a promising concept that proposes interpretable ODE-based structural models from NODEs but relied on manually identifying functional relationships, which can be challenging and prevents full automation. In this work, we present an automated model development approach that combines NODEs with least absolute shrinkage and selection operator (LASSO) regression to automatically propose structural models based on the dynamics learned by NODEs. The approach leverages LASSO's feature selection capability, thereby linking data-driven modeling with interpretable mechanistic structures. We demonstrate the applicability of this automated NODE-LASSO model development approach in three different scenarios: neonatal weight development, bi-exponential PK data, and warfarin PK/PD data. The results indicate that our automated NODE-LASSO model development approach can recover meaningful, mechanism-based structures while reducing the need for extensive iterative and manual model development. This highlights its potential as a resource-efficient and interpretable modeling strategy for PMX and its applications in model-informed drug development and clinical research.
Related Concept Videos
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Pharmacodynamic Models: Overview
Mechanistic Models: Compartment Models in Individual and Population Analysis